RARE Daily

Ultragenyx Sells Portion of Future North American Crysvita Royalties to Omers for $500 Million

July 14, 2022

Ultragenyx Pharmaceutical said it sold 30 percent of its royalty interest from Kyowa Kirin on the future sales of Crysvita in the United States and Canada to Omers, one of Canada’s largest defined benefit pension plans, for $500 million.

Photo: Mardi Dier, chief financial officer of Ultragenyx

Omers’ right to receive royalty payments is based on net sales of the product beginning in April 2023 and total payments are capped at 1.45 times the purchase price.

“In North America, Crysvita has generated more than $1.3 billion net sales in the first four years on the market making it one of the most successful launches in the rare disease field,” said Mardi Dier, chief financial officer of Ultragenyx. “This non-dilutive financing bolsters Ultragenyx’s balance sheet, funds the ongoing commercialization of multiple approved medicines and the advancement of our diverse clinical pipeline.”

Kyowa Kirin and Ultragenyx have been collaborating in the development and commercialization of Crysvita globally. In North America, Crysvita is approved by the U.S. Food and Drug Administration (FDA) and by Health Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older, and FGF23-related hypophosphatemia in tumor induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.

Crysvita (burosumab) is a recombinant fully human monoclonal IgG1 antibody, discovered by Kyowa Kirin, against the phosphaturic hormone FGF23. FGF23 is a hormone that reduces serum levels of phosphorus and active vitamin D by regulating phosphate excretion and active vitamin D production by the kidney. Phosphate wasting in TIO and other hypophosphatemic conditions, including XLH, is caused by excessive levels and activity of FGF23. Crysvita is designed to bind to and thereby inhibit the biological activity of FGF23. By blocking excess FGF23 in patients with TIO and XLH, Crysvita is intended to increase phosphate reabsorption from the kidney and increase the production of vitamin D, which enhances intestinal absorption of phosphate and calcium.

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.